This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
This robust performance is a testimony of the company's agility, resilience and strong execution capabilities during these difficult times
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
Arch Pharma Labs has filed the application
The study was conducted in patients with mild to moderate COVID-19
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Subscribe To Our Newsletter & Stay Updated
